BOTOX® (Botulinum Toxin Type A) as Headache Prophylaxis in Chinese Participants With Chronic Migraine
- Conditions
- Migraine Disorders
- Interventions
- Drug: placebo (sodium chloride 0.9 mg)Biological: botulinum toxin Type A
- First Posted Date
- 2017-06-20
- Last Posted Date
- 2017-07-14
- Lead Sponsor
- Allergan
- Registration Number
- NCT03193346
Safety and Effectiveness of JUVÉDERM VOLUMA® XC Injectable Gel for Correction of Temple Hollowing
- Conditions
- Temple Hollowing
- Interventions
- Device: Juvéderm® VOLUMA XC
- First Posted Date
- 2017-05-25
- Last Posted Date
- 2018-10-18
- Lead Sponsor
- Allergan
- Target Recruit Count
- 1
- Registration Number
- NCT03166618
- Locations
- 🇺🇸
Skin Care and Laser Physicians of Beverly Hills, Los Angeles, California, United States
Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Patients With Osteomyelitis
- First Posted Date
- 2017-03-27
- Last Posted Date
- 2018-09-26
- Lead Sponsor
- Allergan
- Target Recruit Count
- 1
- Registration Number
- NCT03091439
- Locations
- 🇺🇸
Midway Immunology and Research Center, Fort Pierce, Florida, United States
Evaluation of an Alternative Injection Paradigm for OnabotulinumtoxinA (BOTOX®) in the Treatment of Overactive Bladder in Patients With Urinary Incontinence
- Conditions
- Urinary IncontinenceUrinary Bladder, Overactive
- Interventions
- Biological: onabotulinumtoxinADrug: Placebo (saline)
- First Posted Date
- 2017-02-14
- Last Posted Date
- 2019-12-24
- Lead Sponsor
- Allergan
- Target Recruit Count
- 120
- Registration Number
- NCT03052764
- Locations
- 🇺🇸
Urology Clinics of North Texas, Dallas, Texas, United States
🇺🇸Adult and Pediatric Urology, Omaha, Nebraska, United States
🇺🇸Regional Urology, Shreveport, Louisiana, United States
Voiding Efficiency, a Predictor of Clean Intermittent Catheterization (CIC)
- Conditions
- Urinary Bladder, Overactive
- Interventions
- Biological: onabotulinumtoxinA
- First Posted Date
- 2017-02-06
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- Allergan
- Target Recruit Count
- 420
- Registration Number
- NCT03043287
- Locations
- 🇺🇸
Regional Urology, Shreveport, Louisiana, United States
🇺🇸Chesapeake Urology Associates, LLC, Baltimore, Maryland, United States
🇺🇸Virginia Urology, Richmond, Virginia, United States
Efficacy of Ozurdex® in the Treatment of Diabetic Macular Edema (DME)
- First Posted Date
- 2016-12-28
- Last Posted Date
- 2019-03-14
- Lead Sponsor
- Allergan
- Target Recruit Count
- 115
- Registration Number
- NCT03003416
- Locations
- 🇫🇷
CHU Brest, Brest, France
🇫🇷CHU Pasteur 2, Nice, France
🇫🇷CHU Bordeaux, Bordeaux, France
A Study to Evaluate the Effectiveness of Juvéderm® VOLIFT®™ With Lidocaine for Dynamic Radial Cheek Line Skin Depressions
- Conditions
- Cheek Line Depressions
- Interventions
- Device: Juvéderm® VOLIFT®™ with Lidocaine
- First Posted Date
- 2016-12-02
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- Allergan
- Target Recruit Count
- 53
- Registration Number
- NCT02980783
- Locations
- 🇫🇷
Laboratoire DERMSCAN, Lyon, France
Split-face Study Comparing the Cosmetic Efficacy and Tolerability of Two Topical Products in Participants With Moderate Facial Melasma
- Conditions
- Melasma
- Interventions
- Other: Lytera 2.0Drug: 4% Hydroquinone Topical CreamOther: SkinMedica Facial CleanserOther: SkinMedica Rejuvenative MoisturizerOther: SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 Sunscreen
- First Posted Date
- 2016-11-30
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- Allergan
- Target Recruit Count
- 18
- Registration Number
- NCT02977507
- Locations
- 🇺🇸
Mount Sinai St. Luke's Hospital, New York, New York, United States
Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye
- First Posted Date
- 2016-11-17
- Last Posted Date
- 2018-11-30
- Lead Sponsor
- Allergan
- Target Recruit Count
- 43
- Registration Number
- NCT02965846
- Locations
- 🇵🇭
The Medical City, Pasig City, Philippines
🇮🇹Ospedale San Giuseppe, Universita di Milano, Milano, Italy
🇩🇪Ludwig-Maximilians-University, Dept of Ophthalmology, Munich, Germany
Evaluation of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
- Conditions
- Acute Bacterial Skin and Skin Structure Infections
- Interventions
- Drug: Usual Care
- First Posted Date
- 2016-11-11
- Last Posted Date
- 2020-04-10
- Lead Sponsor
- Allergan
- Target Recruit Count
- 313
- Registration Number
- NCT02961764
- Locations
- 🇺🇸
Hartford Hospital, Hartford, Connecticut, United States
🇺🇸Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸Tampa General Hospital, Tampa, Florida, United States